Integra LifeSciences Holdings

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Integra LifeSciences posts solid Q4 results, eyes growth opportunities

Integra LifeSciences delivered strong financial performance in Q4 2022 and full-year 2022, showcasing operational resilience and efficiency amidst supply chain challenges and inflationary pressures.
The company's strategic focus on innovation, international growth, and operational excellence positions it well for sustainable growth in 2023, supported by new product launches and market expansion initiatives.
While facing challenges from supply chain disruptions and inflation, Integra's proactive approach to margin expansion, revenue growth, and strategic investments underscores its commitment to long-term value creation.
With a clear roadmap for 2023, including revenue growth targets, margin improvement strategies, and market expansion plans, Integra is poised to navigate challenges and capitalize on opportunities for continued success.

Integra LifeSciences exceeds Q1 expectations, eyes growth amid challenges

Integra LifeSciences demonstrated resilience and growth potential in Q1 2023, with strong segment performances and strategic initiatives.
While facing challenges like supply constraints and margin pressures, the company remains focused on operational efficiency and growth opportunities.
Reaffirmation of guidance, executive appointments, and proactive strategies position Integra well for future growth and market expansion.
Investors can expect improved performance in the second half, driven by new products, supply chain recovery, and strategic investments.

Integra LifeSciences reports Q2 challenges but shows resilience and growth

Integra LifeSciences navigated challenges from a product recall in Q2, showing resilience with solid profitability and growth in unaffected segments.
The company's strategic focus on returning critical technologies to the market, along with new leadership and financial initiatives, positions it for future success.
Despite challenges, Integra LifeSciences remains confident in regaining market share, sustaining growth momentum, and capitalizing on strategic opportunities.
Operational strengths, market performance, and proactive measures to address challenges underscore the company's resilience and growth potential.

Integra LifeSciences navigates Boston impact, eyes growth opportunities post-remediation

Integra LifeSciences faced challenges from the Boston facility recall but showed resilience with strong performance in key segments. The company is focused on growth opportunities post-Boston remediation and maintains a solid financial position. Analysts are optimistic about the company's ability to recover and grow post-recall.

Integra LifeSciences navigates challenges, eyes global growth opportunities

Integra LifeSciences faced challenges from the Boston recall impacting financials but showcased strengths in strategic product relaunches and divisional growth.
The company's performance metrics for 2023 were mixed, with declines in margins but strong cash flow generation. Opportunities lie in global growth catalysts like CereLink.
Looking ahead, Integra aims for revenue recovery post-Q1 headwinds, emphasizing international expansion and product recovery post-recall.

Integra LifeSciences reports strong Q1 results amidst operational challenges

Integra LifeSciences delivered solid Q1 results driven by revenue growth and successful acquisitions.
While facing challenges with the Boston plant audit and supply constraints, the company is focused on key priorities and opportunities for growth.
Maintaining financial stability with a clear plan to address leverage and uncertainties around product reintroduction.
Investors are closely monitoring the company's progress on key initiatives and leadership transition.

Integra LifeSciences excels in Q2 amidst compliance challenges and growth opportunities

Integra LifeSciences delivered a strong Q2 performance, focusing on operational improvements and compliance enhancements to drive long-term growth and sustainability.
While facing challenges such as revenue impacts from compliance investments and margin pressures, the company remains resilient with a strategic focus on market positioning and efficiency.
With updated guidance, successful acquisition integration, and a CEO search underway, Integra is poised to navigate challenges and capitalize on opportunities for future success.

Integra LifeSciences appoints new CEO amidst revenue challenges in Q3

Integra LifeSciences faced revenue challenges in Q3 2024 due to supply issues and compliance plan implementation. The company announced Mojdeh Poul as the new CEO to drive operational excellence and growth. Despite challenges, revenue diversification and financial stability were maintained, with a focus on future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology. The TT segment focuses on complex wound surgery, surgical reconstruction, and peripheral nerve repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

Besides Wall Street's top -and-bottom-line estimates for Integra (IART), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Integra (IART) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Integra LifeSciences (IART) Q4 Earnings Expected to Decline

PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president and chief executive officer will present at the 42nd Annual J.P. Morgan Healthcare conference on January 10, 2024 at 1:30pm ET.

Integra LifeSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Integra (IART) will be among the top suppliers of ENT products and technologies following the Acclarent acquisition.

Integra (IART) to Advance ENT Division With New Buyout Deal

PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company for $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones. Acclarent is an innovator and market leader in ENT procedures and upon closing, Integra will be one of the leading providers of ENT products and technologies.

Integra LifeSciences Announces Definitive Agreement to Acquire Acclarent®

PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company's board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 2021.

Integra LifeSciences Appoints Jeff Graves, Ph.D., to Board of Directors

DexCom

Haemonetics

Insulet

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Integra Gains From New Product Launches, Mounting Costs Ail

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Why Is Integra (IART) Up 10.2% Since Last Earnings Report?

NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Attention Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ: IART) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 11, 2019 and May 22, 2023. If you suffered a loss on your investment in Integra, contact us about potential recovery by using the link below.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Integra Investors of a Lead Plaintiff Deadline of November 13, 2023

NEW YORK , Nov. 11, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On April 26, 2023, Integra announced.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integra investors who were adversely affected by alleged securities fraud between March 11, 2019 and May 22, 2023.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation(IART) Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Nov. 7, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Integra LifeSciences Holdings Corporation. Shareholders who purchased shares of IART during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Integra LifeSciences Holdings Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 13, 2023 - (NASDAQ: IART)

BENSALEM, Pa. , Nov. 7, 2023 /PRNewswire/ -- Law Offices of Howard G.

IART Investors Have Opportunity to Lead Integra LifeSciences Holdings Corporation Securities Fraud Lawsuit

NEW YORK , Nov. 6, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART) between March 11, 2019 and May 22, 2023, both dates inclusive (the "Class Period"), of the important November 13, 2023 lead plaintiff deadline. SO WHAT: If you purchased Integra common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IART

NEW ORLEANS , Nov. 3, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 13, 2023 to file lead plaintiff applications in a securities class action lawsuit against Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company's shares between March 11, 2019 and May 22, 2023, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of New Jersey.

INTEGRA LIFESCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Integra LifeSciences Holdings Corporation - IART

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Integra To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Integra stock or options between March 11, 2019 and May 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/IART.

INTEGRA SHAREHOLDER ALERT

NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integra investors who were adversely affected by alleged securities fraud between March 11, 2019 and May 22, 2023.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation (IART) Investors of a Class Action Lawsuit and Upcoming Deadline

CEDARHURST, N.Y. , Nov. 1, 2023 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company's shares between March 11, 2019 and May 22, 2023, inclusive (the "Class Period").

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Integra LifeSciences Holdings Corporation - IART

NEW YORK--(BUSINESS WIRE)---- $IART #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwi.

IART INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Integra LifeSciences Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW ORLEANS , Oct. 27, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 13, 2023 to file lead plaintiff applications in a securities class action lawsuit against Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company's shares between March 11, 2019 and May 22, 2023, inclusive (the "Class Period").

INTEGRA LIFESCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Integra LifeSciences Holdings Corporation - 

The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.

Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2023 Earnings Call October 25, 2023 8:30 AM ET Company Participants Chris Ward - Senior Director of Investor Relations Jan De Witte - President and Chief Executive Officer Lea Daniels Knight - Chief Financial Officer Conference Call Participants Young Li - Jefferies Vik Chopra - Wells Fargo Robbie Marcus - J.P. Morgan Ryan Zimmerman - BTIG Craig Bijou - Bank of America Securities Richard Newitter - Truist Securities Steven Lichtman - Oppenheimer and Company Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James David Turkaly - JMP Securities Operator Good day, and thank you for standing by.

News for Integra LifeSciences Holdings Stock (IART)